John snow  Criou um novo artigo
1 d ·Traduzir

Persistent Epithelial Defects: Pipeline Insights, Emerging Therapies & Key Players | Featuring Kala, Eyevance & Amber Ophthalmics | #persistent Epithelial Defects

Persistent Epithelial Defects: Pipeline Insights, Emerging Therapies & Key Players | Featuring Kala, Eyevance &

Persistent Epithelial Defects: Pipeline Insights, Emerging Therapies & Key Players | Featuring Kala, Eyevance &

According to DelveInsight’s latest assessment, the therapeutic pipeline for Persistent Epithelial Defects (PEDs) involves over five pharmaceutical companies actively working on the development of more than five investigational treatments aimed at addressing this challenging ophthalmic di